Optipharm
Cheongju, Ch'ungch'ong-bukto, South Korea
About Optipharm
Optipharm provides a biomedical solution that is involved in the development of cell therapy products using animal stem cells. The company was founded in July 2000 as Avicore Biotechnology Research Center and merged with Medipig Korea and Optipharm Solution Center in December 2007, after which it was renamed Optipharm Solution. It entered the veterinary medicine field in April 2008 by acquiring Farmscare, and it was listed on the KOSDAQ in October 2018 after the company's name was changed to its current name Optipharm in September 2012. It is currently involved in the business of animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, and so on, and it is expanding into the field of human medicine based on the technology that it has accumulated in the field of animal medicine.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Last round: Series Unknown (Jan 2006)
- Website: optipharm.co.kr
- Phone: +82-43-249-7500
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Canonical: https://fsome.com/organization/optipharm-2493077 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.